Note 2023 $’000 2022 $’000 ASSETS Current Assets: Cash and cash equivalents 8 17,094 40,180 Short-term investments 9 211,445 – Trade and other receivables 10 18,617 3,066 Total current assets 247,156 43,246 Non-current assets: Property, plant and equipment 43 21 Deferred tax asset 6 771 – Total non-current assets 814 21 TOTAL ASSETS 247,970 43,267 LIABILITIES AND EQUITY Current liabilities: Trade and other payables 11 3,418 978 Derivative liabilities 12 2,226 700 Income tax payable 6 37,119 – Total current liabilities 42,763 1,678 Total liabilities 42,763 1,678 EQUITY Share capital 13 173,127 167,740 Share option reserve 13 4,382 3,222 Currency translation reserve (10,690) (10,680) Accumulated surplus/(deficit) 38,388 (118,693) Total equity attributable to equity holders 205,207 41,589 TOTAL LIABILITIES AND EQUITY 247,970 43,267 The notes on pages 34 to 50 form part of these consolidated financial statements For and on behalf of the Board of Directors who authorised the issue of these consolidated financial statements on 29 February 2024. CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2023 Patrick Davies Non-Executive Chair Joe Basile Director Neuren Pharmaceuticals Limited Annual Report 2023 31
RkJQdWJsaXNoZXIy MjE2NDg3